Sattva Sukun Lifecare Ltd

Sattva Sukun Lifecare Ltd, a micro-cap player in the retailing sector, has reported a flat financial performance for the quarter ended December 2025, signalling a notable shift from its previously very positive trend. Despite a robust 35.2% growth in net sales, the company’s profitability metrics have deteriorated sharply, with losses widening across key earnings indicators. This mixed performance has led to a downgrade in its Mojo Grade from Strong Sell to Sell, reflecting growing investor caution amid margin pressures and subdued operational efficiency.

Sattva Sukun Lifecare Ltd., a micro-cap retailing company with a market capitalisation of ₹28.00 crores, reported a significant quarterly loss in Q3 FY26, marking a dramatic reversal from its recent profitable performance. The company posted a net loss of ₹0.69 crores for the quarter ended December 2025, representing a steep decline of 188.46% quarter-on-quarter and a 200.00% fall year-on-year. This unexpected deterioration has raised serious questions about the sustainability of the company's business model and its ability to maintain operational profitability.

Sattva Sukun Lifecare Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 26 November 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 11 February 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trends, and technical outlook.

Sattva Sukun Lifecare Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 26 Nov 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 26 December 2025, providing investors with an up-to-date view of its fundamentals, valuation, financial trends, and technical outlook.

Sattva Sukun, a microcap player in the retailing sector, has experienced a revision in its market evaluation reflecting nuanced changes across key analytical parameters. This shift highlights evolving perspectives on the company’s financial health, valuation appeal, and technical outlook amid challenging market conditions.